These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 10492244

  • 21. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS, Tsai YS, Chow NH.
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [Abstract] [Full Text] [Related]

  • 22. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ.
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [Abstract] [Full Text] [Related]

  • 23. [Gene p53 mutations and overexpression of p53 protein in tumors of the Vater's ampulla].
    Terris B, Muzeau F, Sauvanet A, Belghiti J, Fléjou JF.
    Gastroenterol Clin Biol; 1998 May; 22(5):495-9. PubMed ID: 9762287
    [Abstract] [Full Text] [Related]

  • 24. The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.
    Taubert H, Würl P, Bache M, Meye A, Berger D, Holzhausen HJ, Hinze R, Schmidt H, Rath FW.
    Anticancer Res; 1998 May; 18(1A):183-7. PubMed ID: 9568075
    [Abstract] [Full Text] [Related]

  • 25. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
    Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Amato A, Calò V, Dardanoni G, Morello V, La Farina M, Albanese I, Tomasino RM, Gebbia N, Russo A.
    J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
    [Abstract] [Full Text] [Related]

  • 26. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
    Jahnson S, Karlsson MG.
    J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
    [Abstract] [Full Text] [Related]

  • 27. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG.
    Cancer; 2000 Mar 01; 88(5):1091-8. PubMed ID: 10699900
    [Abstract] [Full Text] [Related]

  • 28. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C.
    Mod Pathol; 2001 May 01; 14(5):397-403. PubMed ID: 11353048
    [Abstract] [Full Text] [Related]

  • 29. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
    Offner FA, Schäfer G, Hittmair A, Ofner D, Grünewald K, Weyrer K, Mattern D, Eberle J, Mikuz G, Feichtinger H.
    Verh Dtsch Ges Pathol; 1993 May 01; 77():241-6. PubMed ID: 7511289
    [Abstract] [Full Text] [Related]

  • 30. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG.
    Eur Urol; 2004 Apr 01; 45(4):475-82. PubMed ID: 15041112
    [Abstract] [Full Text] [Related]

  • 31. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM.
    J Urol; 2003 Apr 01; 169(4):1219-28. PubMed ID: 12629332
    [Abstract] [Full Text] [Related]

  • 32. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA, El-Emshaty HM, Tabll A, Elmasry SA, Attallah AM, Gad Elhak NA.
    Hepatogastroenterology; 2004 Apr 01; 51(58):1001-6. PubMed ID: 15239234
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
    Moreno Sierra J, López García Asenjo JA, Redondo González E, Fernández Pérez C, Maestro de las Casas ML, Blanco Jiménez E, Silmi Moyano A, Resel Estévez L.
    Arch Esp Urol; 1999 Oct 01; 52(8):840-8. PubMed ID: 10589115
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Evaluations of protein p53 overexpression in cancer of the bladder: prognostic value].
    Popov Z, Hoznek A, Colombel M, Bastuji S, Abbou CC, Chopin DK.
    Chirurgie; 1996 Oct 01; 121(6):461-9. PubMed ID: 8978142
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma.
    Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H.
    J Urol; 2001 Jan 01; 165(1):42-6; discussion 46. PubMed ID: 11125360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.